Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia (clinicaltrials.gov) - Oct 24, 2026 - P1 | N=132 | Recruiting | Sponsor: Verve Therapeutics, Inc. | N=36 ➔ 132
Enrollment change • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders
|